Accelerate clinical development with better MRD testing
Unmatched sensitivity and specificity for confident MRD detection. Interested in learning more about how Haystack MRD can support your clinical trials?
Haystack MRD™ leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development.
Click to enlarge
Quick View
Haystack MRD Test
Haystack MRD™ is a tumor-informed liquid biopsy test that begins with tissue-based whole exome sequencing (WES) to identify patient-specific tumor mutations. A personalized MRD test is then developed to detect ctDNA from residual, recurrent, or resistant disease.
Click to enlarge
Analytical performance details
Sensitive and accurate ctDNA detection
Haystack MRD is powered by Haystack Duo™ chemistry to achieve sensitivity down to 1 part per million (1 PPM, or 0.0001% tumor fraction) with 100% specificity observed.
Click to enlarge
Confident MRD calls
Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows the calling threshold to be set lower than other methods, which yields the highest sensitivity for patient enrollment, stratification, and response monitoring.
Click to enlarge
Click to enlarge
The multi-tool of MRD
Unlike other tests, Haystack MRD was purpose-built for granular ctDNA testing that reports variant-level results. In addition to reporting sample-level MRD status, Haystack MRD can track specific ctDNA variants for various applications, including targeted therapy guidance.
Each patient’s whole genome library is also archived and is available for acquired resistance mapping and retrospective genomic discovery.
Click to enlarge
Click to enlarge
Contact Us
Get in touch
With our deep roots in liquid biopsy and MRD testing, Haystack Oncology is committed to providing biopharma solutions to improve patient outcomes. Let our unmatched MRD detection capabilities and team of global experts support your clinical cancer research and therapeutic development efforts.
Have questions? We would love to hear from you. Simply click the button below.
Avneet joins Haystack with a deep experience in supporting diagnostic companies with global market access and policy, reimbursement and commercialization strategy, evidence development & value communication.
Previously, Avneet worked in Precision Medicine Commercial Strategy and Market Access consulting, as well as at the UK and Ireland headquarters of Johnson & Johnson, as well as in Healthcare and Life Sciences Investment Banking. In addition to this she has taken on several projects related to intellectual property of drugs. Avneet has an MS from Georgetown University in Biotechnology (BioBusiness Concentration) and a BS in Biochemistry from the University of Leeds, UK.
Joel has overseen financial and business operations for multiple life sciences companies. Most recently, he served as Vice President of Finance & Corporate Development at Sema4, an AI-focused precision medicine company. Previously, Mr. Kaufman served as Chief Business Officer, at Navidea Biopharmaceuticals. He also served as an Equity Research Analyst at Goldman Sachs covering the Life Science Tools, Diagnostics, and Medical Technology sectors. Mr. Kaufman holds an MBA from Northwestern University’s Kellogg School of Management and a BA from the University of Pennsylvania.
With extensive experience in the fields of molecular genetics, cancer biology, and biomedical engineering, Joshua Cohen serves as the Chief Innovation Officer at Haystack Oncology. Working in the lab of Drs. Bert Vogelstein and Kenneth Kinzler, Josh invented and developed the technology upon which Haystack’s Duo™ chemistry is based. His liquid biopsy research served as the basis for a landmark prospective interventional clinical trial demonstrating, for the first time, the use of circulating tumor DNA analyses for the detection of minimal residual disease and selection of adjuvant chemotherapy in stage II colorectal cancer patients.
In recognition of his work, he was named a Lindau Nobel Laureate Young Scientist, received the Michael A. Shanoff Award, and was selected as one of Forbes’ “30 Under 30”. Josh graduated from the Massachusetts Institute of Technology with a B.S. in Chemical-Biological Engineering and obtained a M.Phil. in Computational Biology at the University of Cambridge as a Gates-Cambridge Scholar. He is currently completing his M.D. and Ph.D. from the Johns Hopkins University School of Medicine.
Jen serves as the Director of Pharma Partnering and Strategic Alliances at Haystack Oncology, where she facilitates key collaborations to bring the promise of precision medicine closer to patients. Jen has a background in law, as well as oncology diagnostics and drug development, previously serving in roles at Sysmex Inostics, Natera, and PGDx/Labcorp. Leading with the philosophy that a culture of collaboration is the path forward to improving cancer patient care, Jen engages closely with pharma and healthcare systems to support their research and clinical development programs. Jen holds degrees from Georgetown University and Suffolk University Law School and has over a decade of experience in operations and business development.
Daniel Mehnert leads the bioinformatics department at Haystack Oncology, bringing an extensive background in cancer-related bioinformatics and long-running experience with NGS data analyis in the field of liquid biopies to the team of Haystack Oncology. Prior to joining Haystack, Daniel helped establish several liquid biopsy NGS products by leading the bioinformatics efforts. Daniel received his B.S. and M.S. in Bioinformatics from the Free University of Berlin, where he also worked with hereditery disease detection at the Max Planck Institute for Molecular Genetics.
Mitchell Chan currently serves as an Operating Partner at Catalio Capital Management, LP. and is the acting Chief Financial Officer at Haystack Oncology. Prior to joining Catalio, Mitch was the Chief Financial Officer at Viela Bio (NASDAQ: VIE), where he successfully raised over $750 million, including an initial public offering in 2019, and in 2021, a merger transaction in which Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mitch served as the Director of Investor Relations for AstraZeneca, North America. He also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions.
Mitch earned his BSc. degree in Biochemistry, his MSc. Degree in Medical Biophysics, and his M.B.A. degree from the University of Toronto. He is also the recipient of Executive Certifications from Stanford University, University of California, and the University of Pennsylvania.
With extensive experience in the fields of biomedical engineering and genomics, Joshua serves as the Chief Innovation Officer at Haystack Oncology. Working in the lab of Drs. Bert Vogelstein and Kenneth Kinzler, Josh helped develop Haystack’s Duo™ technology that powers Haystack MRD testing. Joshua holds a B.S. in chemical and biological engineering from the Massachusetts Institute of Technology as well as a M. Phil. in Computational Biology from the University of Cambridge. He is currently completing his M.D., Ph.D. from the Johns Hopkins School of Medicine.
Jared comes to Haystack with the scientific background from a decade of cancer research combined with life science marketing expertise from over a decade in large biotech and small diagnostic startup marketing roles. Jared also co-founded Samba Scientific, a life science marketing agency serving genomic and diagnostic companies around the globe. Jared left Samba to search for a small startup with compelling diagnostic technology where he could focus on building a brand that significantly impacts the human condition. At Haystack, Jared leads an experienced marketing team to help bring the next generation of ctDNA testing to market. Jared completed his Ph.D. in Microbiology & Immunology at the Louisiana State University Health Sciences Center in Shreveport, LA, and post-doctoral training in radiation oncology at the University of North Carolina at Chapel Hill in Chapel Hill, NC.
Hannah Quinn serves as Director of Laboratory Operations at Haystack Oncology. Prior to joining Haystack, Hannah worked at Sysmex-Inostics where she was responsible for clinical laboratory operations, assay implementation, and study management. Before this, Hannah worked for a clinical sequencing laboratory at Johns Hopkins University as part of the clinical testing and R&D teams. Hannah has a BS in Chemistry from Towson University and a MS in Biotechnology from Johns Hopkins University.
Hillary is the Associate Director of Medical Affairs at Haystack Oncology, where she provides key clinical strategy support and primary oversight of the clinical development program. She engages closely with the medical community to establish and execute clinical development initiatives that specifically address current and future needs to improve patient care. Hillary comes to Haystack with a background in molecular diagnostics and liquid biopsy, as well as extensive experience in clinical development and medical scientific affairs roles within the oncology diagnostics industry. Hillary holds a Ph.D. in bioanalytical chemistry from The University of Virginia.
Robert brings an extensive background in molecular genetics and regulated assay development to the team of Haystack Oncology, including more than a decade of experience in the liquid biopsy field. Prior to joining Haystack, Robert served in various technical operations and R&D leadership roles at (Sysmex)-Inostics where he led clinical assay development, implementation and technical support. Robert received his diploma from Johannes Gutenberg University and completed his Ph.D. and postdoctoral training at the Max Planck Institute for Molecular Genetics.
Matt heads up diagnostic development at Haystack and has over a decade of experience in clinical genomics, including purpose-designed liquid biopsy testing, hereditary risk determination, and development and approval of novel companion diagnostics. At Haystack, he bridges our Research & Development Center located in Hamburg, Germany with our clinical laboratory in Baltimore, Maryland, and serves in a combined scientific, technical, and commercial leadership role to help deliver our unique services to patients, globally. In his free time, he enjoys mountain biking, bouldering, and travel.
Frank brings an extensive background in cancer functional genomics and diagnostic assay development to the team of Haystack Oncology, including more than a decade of experience in the liquid biopsy field. Prior to joining Haystack, Frank served in various operations in R&D leadership roles at Inostics and as Chief Scientific Officer at Sysmex Inostics where he led efforts to advance ultra-sensitive digital PCR and NGS-based technologies to clinical grade diagnostic platforms for genetic mutation detection. Frank completed his Ph.D. and postdoctoral training in cancer genomics at the German Cancer Research Center and received his B.S. and M.S. from Heidelberg University.
Dan Edelstein is President and Chief Executive Officer at Haystack Oncology. Dan has over 15 years of liquid biopsy clinical development and commercialization experience. He was previously part of the team at Johns Hopkins that pioneered the use of circulating tumor DNA (ctDNA) to detect and track the progression of cancer. In 2011, while at Inostics, he led the development of the world’s first CLIA laboratory for ctDNA analyses, delivering the first commercially available liquid biopsy assay for clinical practice and prospective clinical trials. Dan was previously the chief commercial officer at Sysmex Inostics where he developed a deep understanding of the clinical requirements for liquid biopsy product development, market access strategies, clinical utility evidence generation and biopharma partnerships.
Dr. Papadopoulos is a professor of oncology and pathology at the Johns Hopkins University School of Medicine. His research focuses in translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer.
Dr. Papadopoulos is internationally known as a co-discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC) and was part of the interdisciplinary team that was first to sequence all of the protein coding genes, determine genetic alterations and construct expression profiles of four common tumor types. Later he was involved in the identification of genetic alterations that drive tumorigenesis in multiple tumor types. His noteworthy discoveries include the identification of novel mutations in chromatin remodeling genes in ovarian clear cell carcinomas and pancreatic neuroendocrine tumors.
Papadopoulos received his B.S. from Aristotelion University of Thessaloniki in Greece. He earned his M.S. in biology at the University of Houston and his Ph.D. in biomedical sciences at the University of Texas Health Science Center at Houston. He completed a Fogerty Fellowship at the National Institute on Aging and a postdoctoral fellowship in oncology at the Johns Hopkins University School of Medicine.
Dr. Kinzler received his Ph.D. from Johns Hopkins University School of Medicince and is now the co-director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center, alongside Dr. Vogelstein. He is consistently ranked among the most highly cited scientists in clinical medicine.
Dr. Kinzler has been recognized for his role in uncovering the genetic alterations linked to the initiation of colon cancer, one of the most common cancers worldwide; development of novel approaches for the molecular analysis of cancer; and more recently, for his role in deciphering the genetic blueprints of many types of cancer.
Kinzler invented SAGE (Serial Analysis of Gene Expression) in the mid-1990s, enabling the first comprehensive analysis of gene expression in human cancer and led him to coin the term “transcriptome”. In the late 1990s and early 2000s, he invented digital PCR and other digital genomics approaches for the detection of trace levels of tumor DNA. In the late 2000s, Kinzler and Ludwig Center co-director Dr. Vogelstein, led a team of scientists who decoded the genomes of many cancers, including breast, colon, pancreatic, brain, ovarian and liver.
Ludwig Center scientists led by Kinzler and Vogelstein have set their sites on developing better methods for detecting cancer early, when it is most curable. Their efforts have led to discoveries in detecting DNA shed from tumors in blood and other body fluids, which were made possible by the digital genomic approaches using the techniques he previously discovered.
Dr. Vogelstein is a Clayton Professor of Oncology and Co-Director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center, along with Dr. Kinzler. He also holds a joint appointment in molecular biology and genetics at The Johns Hopkins University and is a Howard Hughes Medical Institute investigator. Vogelstein's research has been rooted in developing new approaches to the prevention or treatment of cancers by uncovering the genes and pathways that cause the disease. He has won numerous awards for his pioneering studies on the pathogenesis of human cancer, and was the first scientist to elucidate the molecular basis of a common human cancer. His work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies in the future.
Dr. Vogelstein attended the University of Pennsylvania, where he graduated summa cum laude with distinction in mathematics. He obtained his medical degree at the Johns Hopkins University School of Medicine and performed his internship and residency in pediatrics at The Johns Hopkins Hospital. Following his clinical training, Vogelstein completed a postdoctoral fellowship at the National Cancer Institute, focusing on new techniques in molecular biology.
